linerixibat + obeticholic acid

**Linerixibat + obeticholic acid** is a combination of two investigational and approved agents studied primarily for their interaction and potential co-use in cholestatic liver diseases, especially primary biliary cholangitis (PBC). **Linerixibat** is an oral small molecule inhibitor of the ileal bile acid transporter (IBAT), designed to reduce bile acid reabsorption from the intestine, thereby decreasing pruritus (itch) associated with cholestatic disorders[3][5]. **Obeticholic acid** is a potent farnesoid X receptor (FXR) agonist; by activating FXR in the liver and intestines, it downregulates bile acid synthesis and modulates lipid and glucose metabolism[2][4][6]. The combination is under study to evaluate their effects on pharmacokinetics, efficacy, and safety when given together, as both target bile acid pathways involved in PBC[1][7].

Other names

linerixibat + obeticholic acid